Abstract: Defining radiographic treatment success after percutaneous renal ablation is challenging due to variable ablation zone imaging findings over time. The present report describes two cases of progressively more evident enhancing soft-tissue nodules in the perinephric fat more than 2 years after cryoablation. Despite features concerning for tumor recurrence on computed tomography and magnetic resonance imaging, biopsies revealed fat necrosis in both cases. Renal ablation zone soft-tissue nodules can appear long after ablation, enhance with contrast medium, mimic applicator tract or ablation zone tumor seeding, and may require biopsy for confirmation of benignity.
Abstract: Ectopic parathyroid adenomas in the aortopulmonary window (APW) are extremely rare, constituting only 1% of ectopic mediastinal adenomas and 0.24% of all parathyroid adenomas. The authors have encountered three patients with ectopic adenomas in the APW. In each case, the primary arterial supply to the APW adenoma arose from the bronchial artery. In addition, there was a small anastomotic arterial channel connecting the bronchial artery supplying the adenoma to the left inferior thyroid. All three adenomas were treated with transcatheter embolization, with control of hyperparathyroidism in two of three patients. One patient required thoracoscopic removal of the adenoma. It is critical that the interventionalist be aware of this arterial supply pattern to allow successful embolization of an APW ectopic adenoma.
Abstract: Transposition of a deep (9–12 mm) autogenous brachiocephalic vein fistula was required for adequate hemodialysis access in a morbidly obese patient. The patient was a poor candidate for surgical transposition of the upper-arm cephalic vein. As an alternative, retrograde fistula flow was established percutaneously through a 6-F sheath in the forearm cephalic vein with the over-the-wire LeMaitre valvulotome. The retrograde flow in the forearm added 7 cm of superficial vein 6.2–9 mm in diameter with a flow rate of 940–2,868 mL/min, eliminating the need for surgical transposition. The percutaneous technique and required anatomy are described.
Purpose: To identify factors affecting periprocedural morbidity and mortality and long-term survival following hepatic artery embolization (HAE) of hepatic neuroendocrine tumor (NET) metastases.
Purpose: To evaluate the safety and efficacy of transarterial chemoembolization and to identify the prognostic factors associated with survival in patients with hepatocellular carcinoma (HCC) and portal vein (PV) invasion.
Purpose: To report early findings from a prospective United States clinical trial to evaluate the efficacy and safety of prostatic artery embolization (PAE) for benign prostatic hyperplasia (BPH).
Purpose: Hernia complications after creation of a transjugular intrahepatic portosystemic shunt (TIPS) have been reported, although the incidence of this complication is unknown. This study was designed to determine the incidence, morbidity, and outcome of hernia complications in patients with preexisting abdominal or inguinal hernias after TIPS creation.
Abstract: A 29-year-old woman with acute iliofemorocaval thrombosis was discovered to have suprarenal caval agenesis with azygous continuation, hepatic congestion, and fibrosis as a result of chronic Budd–Chiari syndrome. Three staged procedures were performed: pharmacomechanical thrombolysis of acute thromboses, transfemoral liver biopsy and hemodynamic assessment, and percutaneous endovascular creation of a “neocava” lined with endografts. Symptomatic improvement and patency were maintained at 12-week follow-up.
Purpose: To compare survival outcomes of sublobar resection and thermal ablation for early-stage non–small cell lung cancer (NSCLC) in older patients.
Purpose: To assess the safety and efficacy of transcatheter arterial embolization for lower gastrointestinal bleeding (LGIB) and to determine the prognostic factors that affect clinical outcome.
Introduction: Neuroendocrine tumors are a heterogeneous group of slow-growing hormone-secreting neoplasms that can arise from different organ systems throughout the body, including the gastrointestinal and respiratory systems (1–4). Neuroendocrine tumors are categorized as carcinoid tumors and pancreatic neuroendocrine tumors. Carcinoid tumors arise from the enterochromaffin cells of the gastrointestinal tract and airways, and pancreatic neuroendocrine tumors arise from the islet cells of Langerhans. The overall age-adjusted incidence of carcinoids is about two to three cases per 100 000 per year (3,5) and that of pancreatic neuroendocrine tumors is one per 100 000 per year (6). According to the World Health Organization classification, gastroenteropancreatic neuroendocrine tumors have been classified as neuroendocrine neoplasm grade 1–2 and grade 3 neuroendocrine carcinoma, which includes small cell carcinoma and large cell neuroendocrine carcinoma (7). Roughly 46%–93% of patients with neuroendocrine tumors develop liver metastasis, which can involve large portions of liver with associated symptoms.
Introduction: Hepatocellular carcinoma (HCC) is the third most common cause of cancer death worldwide (1). Most patients present with intermediate or advanced disease that is not amenable to curative treatment, and the median survival in this group is 6–8 months (2). Several studies and well-designed randomized trials have shown a positive effect of transcatheter arterial chemoembolization (TACE) on patient outcome and survival (3–11).
Introduction: Budd-Chiari syndrome (BCS) is characterized by the obstruction of the hepatic venous outflow tract from the level of the small hepatic veins to the level of the termination of the inferior vena cava (IVC) into the right atrium in the absence of cardiac disease, pericardial disease, or sinusoidal obstruction syndrome (1). Given the rarity of this disease, no controlled trials have been performed. Accordingly, the current recommendations for the treatment of primary BCS originate from cohort studies and expert opinions (2). A step-wise therapeutic strategy aimed at minimal invasiveness has been adopted, and this strategy proceeds according to the response to therapy (3). This strategy mainly consists of four steps: (a) medical therapy, such as anticoagulation and diuretics; (b) percutaneous recanalization of hepatic veins and/or the IVC; (c) placement of a transjugular intrahepatic portosystemic shunt (TIPS); and (d) orthotopic liver transplantation. Furthermore, a large case series has demonstrated that anticoagulation and TIPS placement have become the mainstay treatment options for BCS in Western countries (4).
Introduction: The diagnosis of benign prostatic hyperplasia (BPH) may be based on three findings: microscopic detection of prostatic hyperplasia (benign proliferation of the stroma and epithelium on the basis of pathologic specimens); palpable enlargement of the prostate, as detected with clinical or ultrasonographic (US) examination; or the presence of lower urinary tract symptoms, such as higher urinary frequency (particularly at night, termed “nocturia”), urinary urgency, urinary leaking, and decreased, hesitant, interrupted urinary stream. However, it is the clinical findings, particularly those indicated by the severity of the lower urinary tract symptoms, that affect the management of these cases.
Introduction: The advent of multidetector computed tomography (CT) has proved invaluable in the rapid evaluation of intraabdominal injuries in patients who sustain multiple trauma (1–9). Multidetector CT has high accuracy for detecting hollow- and solid-organ injury in the trauma setting, including the evaluation for traumatic splenic injuries (1–3,8–10). The detection of active splenic hemorrhage and contained vascular injuries is crucial for identifying the need for subsequent direct intervention (eg, surgery or transcatheter embolization) versus conservative, nonsurgical treatment (1–3,6,7,9,11–15).
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos